CMMB News and Press, Chemomab Therapeutics Ltd. From 09/28/23

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference PR Newswire -- CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Supports Its Disease Modifying Potential in ...

Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire Virtual presentation to be available starting on September 11, 2023 , at 7 AM Eastern Time TEL AVIV, Israel , Aug. 29, 2023 /PRNewswire/ -...

2023-08-14 09:21:23 ET Chemomab Therapeutics press release ( NASDAQ: CMMB ): Q2 GAAP EPS of -$0.04. Cash, cash equivalents and short-term bank deposits were $26.7 million as of June 30, 2023, compared to $32.8 million on March 31, 2023 For further details see: Ch...

Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update PR Newswire ─On Track to Achieve CM-101 PSC Phase 2 Readout Expected in 2H2024— ─Extended Estimated Cash Runway Through PSC Readout and ...

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis PR Newswire --Includes Extensive Data Showing that CM-101, Chemomab's CCL24-Neutralizing Antibody,   Interrupts the Fibro-Inflammatory Process...

2023-06-26 10:08:32 ET Gainers: MoonLake Immunotherapeutics ( MLTX ) +69% . Chemomab Therapeutics ( CMMB ) +33% . Acelyrin ( SLRN ) +22% . ORIC Pharmaceuticals ( ORIC ) +15% . Losers: Avalo Therapeutics ( AVTX ) -85% . Fi...

Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023 PR Newswire --New Proteomics Data Further Confirms the Relationship between CM-101's CCL24 Target and Primary Sclerosing C...

2023-06-22 08:29:19 ET AlloVir ALVR -23% on pricing $75M of stock offering. Advanced Health Intelligence ( AHI ) -22% . InMed Pharmaceuticals ( INM ) -19% announces results from a phase 2 clinical trial in epidermolysis bullosa . Innovative Eyewear ...

2023-06-21 10:07:44 ET Gainers: Ocean Biomedical ( OCEA ) +43% . PetVivo Holdings ( PETV ) +23% . Patterson Companies ( PDCO ) +14% . Zentalis Pharmaceuticals ( ZNTL ) +5% . RenovoRx ( RNXT ) +4% . Losers: uniQure ( ...

Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 PR Newswire ─ Treatment with CM-101 Improves Additional Biomarkers of Fibrosis and Inflammation, `Reinforcing and Extending Initial S...